HKW Portfolio Company Infab Acquires Another Complementary Product Line

HKW, a middle-market private equity firm focused on growth-oriented companies; today announced that its portfolio company, Infab, LLC (“Infab”), has acquired the glove division of International Biomedical, Ltd.

The gloves are designed to reduce the amount of radiation exposure during surgical procedures. The financial terms of the transaction were not disclosed.

“This acquisition is a very logical fit with Infab as it adds a radiation protection product of exceptional quality to our offering,” said Daren Dickerson, CEO of Infab. “The Infab team is very excited to add these gloves to our production so that we can be more responsive in providing critical products to healthcare professionals.”

“John Segars, CEO of International Biomedical, has done a remarkable job building the glove business. We are very pleased to bring this excellent product line to leading healthcare customers worldwide,“ said Kent Robinson, HKW Partner and Chairman of the Board for Infab. “HKW’s emphasis on partnering in the health and wellness industry remains a key area of focus; this add-on strengthens our commitment to support the professionals within this sector.


Infab designs and builds lightweight, comfortable, and technologically advanced radiation protection products. Infab’s PPE products enable health care providers and patients to benefit from the diagnostic capabilities of imaging technology, functioning as a “one-stop-shop” for distributors and customers.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.